Amer Zeidan, Professor of Medicine, Chief of Hematologic Malignancies, Director of Heme Clinical Research at Yale University, shared a post on LinkedIn:
“What a fantastic news and a big win for our patients and AML field.
Very excited about the combination treatments that are being run with ziftomenib.
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation.”
More posts featuring Ziftomenib.